10-K: enVVeno Medical Shifts Focus to Non-Surgical Venous Valve After VenoValve FDA Rejection

enVVeno Medical Corporation received a non-approvable letter from the FDA for its VenoValve, prompting a strategic pivot to its next-generation enVVe System, a non-surgical venous valve, with pivotal trials expected to begin in 2026.

Summary

• enVVeno Medical Corporation is a medical device company developing bioprosthetic solutions for chronic venous disease (CVD), specifically Chronic Venous Insufficiency (CVI).
• The company's first product, VenoValve, a surgical replacement venous valve, received a non-approvable letter from the FDA in August 2025, and a subsequent appeal was unsuccessful.
• The company is now focused on its next-generation product, the enVVe System, a first-in-class, non-surgical, transcatheter-based replacement venous valve for severe CVI.
• Pre-clinical testing for the enVVe System is complete, and discussions with the FDA for the enVVe pivotal trial have begun, with the trial expected to commence in 2026.
• The company reported net losses of $19.5 million for the year ended December 31, 2025, an 11% decrease from $21.8 million in 2024.
• Research and development expenses decreased by $2.2 million (19%) to $10.0 million in 2025, primarily due to lower VenoValve study costs.
• Selling, general and administrative expenses decreased by $0.7 million (6%) to $10.9 million in 2025, mainly due to lower non-recurring legal costs in 2024.
• Other income decreased by $0.6 million to $1.4 million in 2025, as the company held fewer U.S. Treasury securities.
• Cash and cash equivalents were $3.1 million, and investments were $25.1 million, totaling $28.2 million as of December 31, 2025.
• The company used $15.6 million in cash from operating activities in 2025.
• A one-for-thirty-five (1:35) reverse stock split became effective on January 20, 2026, to maintain Nasdaq listing compliance, which was achieved by February 4, 2026.
• As of March 24, 2026, there were 655,521 shares of common stock outstanding, and the aggregate market value of non-affiliate common stock was $76.1 million as of June 30, 2025.
• Jennifer Bright was appointed Chief Financial Officer in May 2025, replacing Craig Glynn.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the definitive FDA rejection of the VenoValve, which was the company's lead product. While the pivot to the enVVe System offers a future path, it is an earlier-stage product with significant regulatory and development hurdles still ahead, prolonging the timeline to potential profitability and necessitating further capital raises.

Positives

• Net loss decreased by 11% to $19.5 million in 2025 compared to $21.8 million in 2024.
• The company has completed pre-clinical testing for its next-generation enVVe System and is in discussions with the FDA for a pivotal trial expected in 2026.
• The enVVe System is a non-surgical, transcatheter-based replacement venous valve, which is expected to broaden adoption by appealing to a wider range of implanting physicians.
• The company operates an ISO 13485-2016 certified manufacturing facility with capacity to produce up to approximately 20,000 venous valves per year.
• Management believes current capital resources are sufficient to fund operations through mid-2027.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.

Negatives

• The FDA issued a non-approvable letter for the VenoValve in August 2025, and a subsequent appeal was unsuccessful, leading the company to forego further commercialization efforts for VenoValve.
• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• Operating cash flow was negative, with $15.6 million used in operating activities in 2025.
• The company is entirely dependent on the successful and timely regulatory approval and commercialization of the enVVe System, which may never receive FDA approval.
• The VenoValve's FDA rejection cited insufficient data to determine a favorable benefit-risk profile, concerns about bias in clinical improvement data, and safety concerns related to the open surgical procedure.

Risks

• Incurring significant losses in the future and potentially never achieving or sustaining profitability.
• Dependence on successful and timely regulatory approval and commercialization of the enVVe System, which may not receive approval.
• Market acceptance of products, if approved, by surgeons and patients is uncertain.
• Failure to scale up the manufacturing process of product candidates in a timely manner or at all.
• Ability to retain and recruit key personnel, including developing a sales and marketing infrastructure.
• Reliance on a few third-party suppliers for porcine tissue and other components, making the company vulnerable to supply problems and price fluctuations.
• Difficulty demonstrating the efficacy and financial viability of products to doctors, hospitals, insurance companies, and other stakeholders.
• Significant competition in the medical device industry and the need to continuously develop and enhance product candidates.
• Limited manufacturing resources and the risk of disruption to the Irvine, California facility.
• Product liability lawsuits could result in substantial liabilities, limit sales, and harm the business.
• Loss of executive officers or inability to attract and retain qualified personnel.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to ownership changes.
• Extensive governmental regulation and oversight by the FDA and foreign authorities, with failure to comply potentially harming the business.
• Uncertainty whether clinical trials will meet desired endpoints, produce meaningful data, or be free of unexpected adverse effects.
• The FDA regulatory approval process is complex, time-consuming, and unpredictable, potentially extended by workforce reductions.
• Failure to comply with ongoing regulatory requirements or unanticipated problems with products could lead to restrictions or market withdrawal.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain approvals or market products.
• Subject to federal, state, and foreign healthcare laws and regulations (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), with non-compliance leading to substantial penalties.
• Relationships with physician consultants, owners, and investors could face scrutiny from regulatory enforcement authorities.
• Inability to adequately protect proprietary technology or obtain and maintain issued patents.
• Substantial costs from litigation or other proceedings relating to patent and other intellectual property rights.
• Volatility in the trading price of securities due to various factors, including regulatory decisions and financial performance.
• Significant dilution from the issuance of a large number of options and warrants, and potential future capital raises.
• Failure to meet Nasdaq's continued listing requirements could result in de-listing.
• Provisions in charter documents or Delaware law could delay or prevent an acquisition, making it difficult to change management.
• No anticipation of paying cash dividends in the foreseeable future, making capital appreciation the sole source of gain.

Future Outlook

The company expects a moderate overall increase in expenses from current levels as VenoValve pivotal study costs continue and enVVe pivotal study costs begin if IDE approval is received. The enVVe pivotal trial is expected to begin in 2026. Management anticipates a cash burn rate increase from approximately $4 million per quarter to between $4 million and $5 million per quarter in 2026, but believes current capital resources are sufficient to fund operations through mid-2027. The company will need to raise additional capital in the future to complete product development and penetrate markets.

Management Comments

• "We cannot provide any assurance that enVVe will receive approval from the FDA."
• "There are currently no devices approved as surgical or non-surgical replacement venous valves, and there are currently no effective treatments for deep venous CVI caused by incompetent valves."
• "The Company has completed pre-clinical testing on the enVVe System and has begun discussions with the FDA regarding the enVVe pivotal trial, which it expects to begin in 2026."
• "The Companys strategy was to first develop the VenoValve, and then to transition to enVVe. That strategy remains intact. The enVVe System could not have been developed without the experience gained from the VenoValve."
• "Because the VenoValve was not approved by the FDA, the Company has elected to forego any potential approval and commercialization efforts outside of the U.S. for the VenoValve and to instead focus its resources on bringing enVVe to market."
• "Clinicians recognize the need for a replacement venous valve for patients suffering from deep venous CVI and both the short-term and long-term VenoValve efficacy data has been extremely promising for this difficult to treat patient population."
• "Although interest in a surgical replacement venous valve has been strong, clinicians recognize that long-term the large potential market is best served via a trans-catheter delivered iteration of the device."
• "There continues to be significant interest from clinicians wanting to participate in the enVVe pivotal study."
• "Management believes that our capital resources are sufficient to meet our obligations as they become due within one year after the date of this Annual Report."

Industry Context

StockSavvy.ai notes that enVVeno Medical operates in the highly competitive and rapidly evolving medical device industry, specifically targeting Chronic Venous Insufficiency (CVI), a prevalent condition with no currently approved surgical or non-surgical replacement venous valves. The company's pivot from a surgical VenoValve to a transcatheter enVVe System aligns with a broader industry trend towards less invasive procedures, potentially expanding market adoption among a wider range of interventional physicians. The FDA's rigorous review process, as evidenced by the VenoValve's non-approvable letter, underscores the high regulatory hurdles for novel Class III medical devices, particularly in areas without established regulatory pathways or benchmarks for effectiveness.

Comparison to Industry Standards

• The company operates in a market segment (deep venous CVI with incompetent valves) where there are currently no FDA-approved surgical or non-surgical replacement venous valves, indicating a significant unmet medical need and a potential first-in-class opportunity for the enVVe System.
• The FDA's rejection of the VenoValve due to insufficient data on benefit-risk profile and lack of a specific hemodynamic measurement for patient improvement highlights the challenge of establishing new regulatory pathways for novel devices without existing industry or regulatory standards, a hurdle that the enVVe System will also face.
• The shift to a transcatheter approach for the enVVe System is consistent with broader trends in cardiovascular device development, where companies like Edwards Lifesciences (mentioned in Dr. Duhay's background for TAVR) have successfully transitioned from surgical to minimally invasive solutions for heart valve therapies, suggesting a viable strategic direction if regulatory and clinical milestones are met.

Management Changes

Corporate Governance

Legal Proceedings

• None mentioned in Item 3. Legal Proceedings.

Related Party Transactions

• None disclosed other than equity and other compensation, termination, change in control, and similar arrangements for officers and directors.

Stakeholder Impact

• **Shareholders**: Face significant uncertainty and potential dilution from future capital raises. The FDA rejection of VenoValve and the shift to an earlier-stage product prolongs the path to profitability. The reverse stock split was a technical measure to maintain listing, but does not fundamentally change underlying value.
• **Employees**: The company's continued losses and dependence on future product approvals create job security risks. However, the focus on the enVVe System provides a new strategic direction and continued R&D activity.
• **Customers (Physicians/Hospitals)**: The unmet need for deep venous CVI treatment remains. The company's pivot to a non-surgical solution (enVVe) could be appealing if approved, but the VenoValve's rejection may cause caution.
• **Patients**: Patients suffering from severe CVI continue to lack effective treatments. The enVVe System offers potential hope for a less invasive solution, but its availability is years away and subject to regulatory approval.
• **Creditors/Suppliers**: The company's liquidity position, with $28.2 million in cash and investments, provides a runway through mid-2027, but ongoing losses and the need for future capital raises indicate potential reliance on external financing.

Next Steps

• Begin the enVVe pivotal trial in 2026, following discussions with the FDA.
• Continue to incur costs for the VenoValve pivotal study follow-up.
• Increase or scale up production processes for commercialization of enVVe, if approved.
• Establish a sales and marketing infrastructure for enVVe, if approved.
• Seek additional funds in the future through equity or debt financings, or strategic alliances.
• Comply with ongoing regulatory requirements for any approved products and manufacturing processes.
• Continue to develop and enhance product candidate offerings and potentially introduce new product candidates.

Key Dates

Recommendation

The FDA's non-approvable letter for the VenoValve is a significant setback, eliminating the company's most advanced product from the market. While the pivot to the enVVe System offers a promising non-surgical approach, it is still in early stages with pivotal trials not expected until 2026, implying a long and uncertain path to commercialization and profitability. The company has sufficient cash for operations through mid-2027, which provides some stability, but future capital raises will be necessary and could lead to further dilution. Given the high-risk nature of medical device development, particularly after a major regulatory rejection, and the early stage of the new lead product, a 'hold' recommendation is appropriate. Investors should monitor progress on the enVVe pivotal trial and future financing activities closely, as the risk-reward profile remains highly speculative.

Keywords

Medical Device, Venous Disease, Chronic Venous Insufficiency, CVI, enVVe System, VenoValve, FDA Approval, Transcatheter Valve, Bioprosthetic, Clinical Trials, NASDAQ, NVNO, Healthcare Regulation, Medical Technology